| 0.522 0 (0%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.12 | 1-year : | 3.37 |
| Resists | First : | 1.81 | Second : | 2.89 |
| Pivot price | 0.32  |
|||
| Supports | First : | 0.08 | Second : | 0.07 |
| MAs | MA(5) : | 0.18 | MA(20) : | 0.54 |
| MA(100) : | 4.02 |
MA(250) : | 6.28 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 19.6 |
D(3) : | 7.4 |
| RSI | RSI(14): 39.7 |
|||
| 52-week | High : | 16.2 | Low : | 0.08 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABP ] has closed below upper band by 28.4%. Bollinger Bands are 49.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.76 - 0.76 | 0.76 - 0.77 |
| Low: | 0.52 - 0.52 | 0.52 - 0.52 |
| Close: | 0.52 - 0.52 | 0.52 - 0.53 |
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Sat, 21 Feb 2026
Abpro Holdings Faces Nasdaq Delisting, Plans Appeal - The Globe and Mail
Fri, 20 Feb 2026
Abpro Holdings (NASDAQ: ABP) hit with Nasdaq delisting, eyes OTC Pink trading - Stock Titan
Tue, 10 Feb 2026
This Is Why Abpro Stock (ABP) Surged Today - TipRanks
Thu, 15 Jan 2026
Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Thu, 15 Jan 2026
New HER2 T-cell drug ABP-102 moves toward global trial after FDA nod - Stock Titan
Tue, 06 Jan 2026
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 34.9 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -8.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -229.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.55 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | -0.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|